カテゴリ： GlobalData, ドイツ, 企業調査

Boehringer Ingelheim GmbH：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Boehringer Ingelheim GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3465
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：146
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Boehringer Ingelheim GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG is a pharmaceutical company that conducts research, development, manufacture and sale of pharmaceuticals. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used in the treatment of central nervous system disorders, respiratory diseases, cardiovascular diseases, metabolic disorders, cancer, urological and viral conditions, among others. It operates facilities for manufacture pharmaceuticals, chemical active substances, and medical products. Boehringer operates globally through affiliates and is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

Boehringer Ingelheim GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 8
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
Boehringer Ingelheim GmbH, Medical Devices Deals, 2012 to YTD 2018 13
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deal Details 20
Asset Purchase 20
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 20
Merial Acquires Manufacturing Facility from Merck 22
Boehringer Ingelheim To Acquire Global Rights To FX125L And Somatotaxin Portfolio From Funxional Therapeutics 23
Boehringer Ingelheim Plans To Acquire OTC Brands In India 24
Boehringer Ingelheim Acquires PDE2 Inhibitors Platform From biocrea 25
Partnerships 26
Boehringer Ingelheim, Imperial College London, University of Oxford, University of Edinburgh, Imperial Innovations, and Oxford BioMedica Enter into Collaboration Agreement 26
Bactevo Enters into Drug Discovery Agreement with Boehringer Ingelheim 28
Topas Therapeutics Enters into Agreement with Boehringer Ingelheim 29
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 30
Prime Therapeutics Enters into Agreement with Boehringer Ingelheim 31
Adimab Enters into Agreement with Boehringer Ingelheim 32
Evox Therapeutics Enters into Research Agreement with Boehringer Ingelheim 33
Boehringer Ingelheim Enters into Co-Development Agreement with Roche 34
Boehringer Ingelheim Enters into Agreement with Autifony Therapeutics 35
BioMed X and Boehringer Ingelheim Enter into Research Partnership 36
HitGen Enters into Research Agreement with Boehringer Ingelheim 37
Anthem, HealthCore and Boehringer Ingelheim Enter into Agreement 38
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 39
Geisinger Enters into Agreement with Boehringer Ingelheim 40
Anagenesis Biotechnologies Enters into Research Agreement with Boehringer Ingelheim 41
Boehringer Ingelheim Enters into Partnership with Peking University 42
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 43
Boehringer Ingelheim Enters into Agreement with Weill Cornell Medicine 44
Boehringer Ingelheim Enters into Research Agreement with China Southeast University 45
Boehringer Ingelheim Enters into Agreement with Esteve 46
leadXpro to Enter into Agreement with Boehringer Ingelheim 47
Boehringer Ingelheim Expands Agreement with Sarah Cannon Research Institute 48
Boehringer Ingelheim Enters into Agreement with ViraTherapeutics 49
Boehringer Ingelheim Enters into Research Agreement with Saniona 50
Boehringer Ingelheim and University of Dundee Enter into Agreement 51
Eli Lilly Enters into Agreement with Boehringer Ingelheim 52
Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute 53
Boehringer Ingelheim Enters into Research Agreement with BioMed X 54
LDC, Max Planck Innovation Enters into Agreement with Boehringer Ingelheim 55
Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 56
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 57
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center 58
Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine 59
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 61
Boehringer Ingelheim and Philogen Enter into Partnership 62
Boehringer Ingelheim Enters into Partnership with Circuit Therapeutics 63
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 64
Boehringer Ingelheim Enters into Research Agreement with Vanderbilt University 65
Boehringer Ingelheim Extends Research Agreement with BioMed X 66
Boehringer Ingelheim Enters into Distribution Agreement with C-squared PHARMA 67
Hydra Biosciences Enters Into R&D Agreement With Boehringer Ingelheim 68
Crystal Biosciences Expands its Agreement with Boehringer Ingelheim to Discover and Develop Therapeutic Antibodies 69
Circuit Therapeutics Enters Into Research Agreement With Boehringer Ingelheim For Drug Discovery 70
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 71
Beactica Expands Drug Discovery Agreement With Boehringer Ingelheim 72
Diaxonhit Enters Into Research Agreement With Boehringer Ingelheim For Epitope Targets 73
Boehringer Ingelheim And Shanghai Zhangjiang Biotech Form R&D Joint Venture 74
Novation Pharma Enters into Research Agreement with Boehringer Ingelheim 75
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 76
Boehringer Ingelheim Enters Into Research Agreement With ETH Zurich 77
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 78
Licensing Agreements 79
Boehringer Ingelheim Exercises Option for Licensing Agreement with Eureka Therapeutics 79
Boehringer Ingelheim Enters into Licensing Agreement with OSE Immunotherapeutics 80
Boehringer Ingelheim Enters into Licensing Agreement with Distributed Bio for SuperHuman Platform 81
Xynomic Pharma Enters into Licensing Agreement with Boehringer Ingelheim 82
Boehringer Ingelheim Enters into Licensing Agreement with Gubra 83
Boehringer Ingelheim Enters into Licensing Agreement with Philogen 84
Amgen Acquires Right to BI 836909 from Boehringer Ingelheim 85
Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 86
Hydra Biosciences Enters into Licensing Agreement with Boehringer Ingelheim 87
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 88
Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 90
Zealand Pharma Enters into Licensing Agreement with Boehringer 91
Connexios Life Sciences Enters Into Licensing Agreement With Boehringer Ingelheim Sciences For CNX-012 92
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 94
Fibrostatin Enters into Licensing Agreement with Boehringer Ingelheim 95
BaroFold To Enter Into Licensing Agreement With Boehringer Ingelheim For PreEMT 96
Polyphor Extends Licensing Agreement with Boehringer Ingelheim 97
Boehringer Ingelheim to Enter into Licensing Agreement with PROvendis 98
Boehringer Ingelheim Enters into Licensing Agreement with Vectron Biosolutions 99
Vivalis Enters Into Licensing Agreement With Merial For EB66 Cell Line 100
Asset Transactions 101
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 101
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 102
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 104
Centrexion Therapeutics Acquires Three New Analgesic Candidates from Boehringer Ingelheim 105
C-squared PHARMA Acquires Phytochemical API Portfolio from Boehringer Ingelheim 106
Boehringer Ingelheim GmbH – Key Competitors 107
Boehringer Ingelheim GmbH – Key Employees 108
Boehringer Ingelheim GmbH – Locations And Subsidiaries 109
Head Office 109
Other Locations & Subsidiaries 109
Recent Developments 111
Financial Announcements 111
Aug 01, 2018: Boehringer Ingelheim achieves modest growth in the first half of 2018 111
Aug 02, 2017: Boehringer Ingelheim Achieves Good Growth in the First Half of 2017 112
Apr 05, 2017: Successful financial year 2016 for Boehringer Ingelheim 113
Research And Development 114
Nov 27, 2017: BioMed X and Boehringer Ingelheim Start New Joint Research Group in Bacterial Modulation of Innate Immunity 114
Corporate Communications 115
Jan 31, 2018: Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018. Wolfgang Baiker Appointed U.S. President & CEO Effective March 1, 2018. 115
Dec 15, 2017: Change in the Board of Managing Directors at Boehringer Ingelheim 116
Government and Public Interest 117
Mar 21, 2018: Leukemia Patient’s Legacy Helps Drive Innovative Cancer Clinical Trial 117
Feb 21, 2018: Boehringer Ingelheim: 2018 European PRRS Research Award open for submissions until July 1st 119
Product News 120
Oct 10, 2017: Innovative thrombolytics for acute myocardial infarction readily accessible for Russian patients 120
07/19/2017: OSE Immunotherapeutics Receives €9.2 million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM) 121
Jul 14, 2018: Boehringer Ingelheim unveils 15 new medicines 122
Jun 21, 2017: New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients 123
May 16, 2017: Commercial batches of localized innovative thrombolytics to be launched to Russian market in June 124
05/15/2017: OSE Immunotherapeutics Presents New Data on Anti-SIRPa, the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress” 126
05/15/2017: Pharmaxis Drug Discovery Set To Generate Further €10M Milestone Payment In 2017 As Boehringer Confirms Second Clinical Study 127
Clinical Trials 128
Jul 12, 2018: Saniona receives milestone payment from Boehringer Ingelheim 128
Mar 19, 2018: OSE Immunotherapeutics to Present New Data on OSE-172 at American Association for Cancer Research Annual Meeting 2018, in Chicago, April 14-18 129
Mar 15, 2018: MabVax Therapeutics to present results from preclinical work on anti-cancer drug 130
Oct 02, 2017: OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment 131
Aug 24, 2017: Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH 132
May 11, 2017: Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim 133
Apr 05, 2017: OSE Immunotherapeutics Presented New Data at AACR Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Antitumoral Potent T Memory Response 134
Feb 21, 2017: OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 at the 24th Molecular Med TRI-CON 2017 Meeting 135
Other Significant Developments 136
Jul 04, 2018: Boehringer Ingelheim extends “one-stop-shop” service with new fill & finish capabilities in China 136
Apr 25, 2018: Boehringer Ingelheim has a very successful 2017 financial year 137
Apr 11, 2018: Investment Of 65 Million Euro In Avian Vaccines In France 138
Feb 16, 2018: Read moreon Systemic Sclerosis World Congress: Inspirational patient stories reveal the challenging realities of living with devastating rare disease 139
Feb 16, 2018: Systemic Sclerosis World Congress: Inspirational patient stories reveal the challenging realities of living with devastating rare disease 140
Feb 12, 2018: Boehringer Ingelheim Demonstrates their Commitment to Site Relationships by Joining SCRS’ Global Impact Partner Program 141
Nov 20, 2017: Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential 142
Jul 31, 2017: Boehringer Ingelheim And Lilly To Support New American College Of Cardiology Program To Highlight The Increasingly Important Role Of Cardiologists In Reducing Cardiovascular Risk 143
Mar 13, 2017: FORMA Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim 144
Mar 02, 2017: Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million 145
Appendix 146
Methodology 146
About GlobalData 146
Contact Us 146
Disclaimer 146

List of Tables
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Boehringer Ingelheim GmbH, Deals By Therapy Area, 2012 to YTD 2018 12
Boehringer Ingelheim GmbH, Medical Devices Deals, 2012 to YTD 2018 13
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 20
Merial Acquires Manufacturing Facility from Merck 22
Boehringer Ingelheim To Acquire Global Rights To FX125L And Somatotaxin Portfolio From Funxional Therapeutics 23
Boehringer Ingelheim Plans To Acquire OTC Brands In India 24
Boehringer Ingelheim Acquires PDE2 Inhibitors Platform From biocrea 25
Boehringer Ingelheim, Imperial College London, University of Oxford, University of Edinburgh, Imperial Innovations, and Oxford BioMedica Enter into Collaboration Agreement 26
Bactevo Enters into Drug Discovery Agreement with Boehringer Ingelheim 28
Topas Therapeutics Enters into Agreement with Boehringer Ingelheim 29
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 30
Prime Therapeutics Enters into Agreement with Boehringer Ingelheim 31
Adimab Enters into Agreement with Boehringer Ingelheim 32
Evox Therapeutics Enters into Research Agreement with Boehringer Ingelheim 33
Boehringer Ingelheim Enters into Co-Development Agreement with Roche 34
Boehringer Ingelheim Enters into Agreement with Autifony Therapeutics 35
BioMed X and Boehringer Ingelheim Enter into Research Partnership 36
HitGen Enters into Research Agreement with Boehringer Ingelheim 37
Anthem, HealthCore and Boehringer Ingelheim Enter into Agreement 38
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 39
Geisinger Enters into Agreement with Boehringer Ingelheim 40
Anagenesis Biotechnologies Enters into Research Agreement with Boehringer Ingelheim 41
Boehringer Ingelheim Enters into Partnership with Peking University 42
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 43
Boehringer Ingelheim Enters into Agreement with Weill Cornell Medicine 44
Boehringer Ingelheim Enters into Research Agreement with China Southeast University 45
Boehringer Ingelheim Enters into Agreement with Esteve 46
leadXpro to Enter into Agreement with Boehringer Ingelheim 47
Boehringer Ingelheim Expands Agreement with Sarah Cannon Research Institute 48
Boehringer Ingelheim Enters into Agreement with ViraTherapeutics 49
Boehringer Ingelheim Enters into Research Agreement with Saniona 50
Boehringer Ingelheim and University of Dundee Enter into Agreement 51
Eli Lilly Enters into Agreement with Boehringer Ingelheim 52
Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute 53
Boehringer Ingelheim Enters into Research Agreement with BioMed X 54
LDC, Max Planck Innovation Enters into Agreement with Boehringer Ingelheim 55
Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 56
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 57
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center 58
Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine 59
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 61
Boehringer Ingelheim and Philogen Enter into Partnership 62
Boehringer Ingelheim Enters into Partnership with Circuit Therapeutics 63
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 64
Boehringer Ingelheim Enters into Research Agreement with Vanderbilt University 65
Boehringer Ingelheim Extends Research Agreement with BioMed X 66
Boehringer Ingelheim Enters into Distribution Agreement with C-squared PHARMA 67
Hydra Biosciences Enters Into R&D Agreement With Boehringer Ingelheim 68
Crystal Biosciences Expands its Agreement with Boehringer Ingelheim to Discover and Develop Therapeutic Antibodies 69
Circuit Therapeutics Enters Into Research Agreement With Boehringer Ingelheim For Drug Discovery 70
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 71
Beactica Expands Drug Discovery Agreement With Boehringer Ingelheim 72
Diaxonhit Enters Into Research Agreement With Boehringer Ingelheim For Epitope Targets 73
Boehringer Ingelheim And Shanghai Zhangjiang Biotech Form R&D Joint Venture 74
Novation Pharma Enters into Research Agreement with Boehringer Ingelheim 75
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 76
Boehringer Ingelheim Enters Into Research Agreement With ETH Zurich 77
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 78
Boehringer Ingelheim Exercises Option for Licensing Agreement with Eureka Therapeutics 79
Boehringer Ingelheim Enters into Licensing Agreement with OSE Immunotherapeutics 80
Boehringer Ingelheim Enters into Licensing Agreement with Distributed Bio for SuperHuman Platform 81
Xynomic Pharma Enters into Licensing Agreement with Boehringer Ingelheim 82
Boehringer Ingelheim Enters into Licensing Agreement with Gubra 83
Boehringer Ingelheim Enters into Licensing Agreement with Philogen 84
Amgen Acquires Right to BI 836909 from Boehringer Ingelheim 85
Boehringer Ingelheim Exercises Option for Licensing Agreement with Inventiva 86
Hydra Biosciences Enters into Licensing Agreement with Boehringer Ingelheim 87
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 88
Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 90
Zealand Pharma Enters into Licensing Agreement with Boehringer 91
Connexios Life Sciences Enters Into Licensing Agreement With Boehringer Ingelheim Sciences For CNX-012 92
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 94
Fibrostatin Enters into Licensing Agreement with Boehringer Ingelheim 95
BaroFold To Enter Into Licensing Agreement With Boehringer Ingelheim For PreEMT 96
Polyphor Extends Licensing Agreement with Boehringer Ingelheim 97
Boehringer Ingelheim to Enter into Licensing Agreement with PROvendis 98
Boehringer Ingelheim Enters into Licensing Agreement with Vectron Biosolutions 99
Vivalis Enters Into Licensing Agreement With Merial For EB66 Cell Line 100
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 101
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 102
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 104
Centrexion Therapeutics Acquires Three New Analgesic Candidates from Boehringer Ingelheim 105
C-squared PHARMA Acquires Phytochemical API Portfolio from Boehringer Ingelheim 106
Boehringer Ingelheim GmbH, Key Competitors 107
Boehringer Ingelheim GmbH, Key Employees 108
Boehringer Ingelheim GmbH, Other Locations 109
Boehringer Ingelheim GmbH, Subsidiaries 109

List of Figures
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
Boehringer Ingelheim GmbH, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[Boehringer Ingelheim GmbH：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Petrobras Argentina SA：石油・ガス：M&Aディール及び事業提携情報
    Summary Petrobras Argentina SA (PESA), a subsidiary of Pampa Energia S.A, is an integrated energy company. It carries out the exploration and production of crude oil and natural gas, refining of crude oil, transportation, and marketing of oil and refined products. The company’s product portfolio inc …
  • InviCRO LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary InviCRO LLC (InviCRO) a subsidiary of Konica Minolta Inc, is a provider of image informatics, engineering and operational services in translational drug discovery and development. The company developed VivoQuant, a DICOM compliant post-processing suite for image data combining fundamental vi …
  • Wellington Pub Company PLC：企業の戦略・SWOT・財務情報
    Wellington Pub Company PLC - Strategy, SWOT and Corporate Finance Report Summary Wellington Pub Company PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Rexnord Corp (RXN)：企業の財務・戦略的SWOT分析
    Rexnord Corp (RXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Bilcare Ltd (526853)：企業の財務・戦略的SWOT分析
    Bilcare Ltd (526853) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Koc Holding AS：企業の戦略・SWOT・財務情報
    Koc Holding AS - Strategy, SWOT and Corporate Finance Report Summary Koc Holding AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Washington University in St Louis-製薬・医療分野：企業M&A・提携分析
    Summary Washington University in St Louis (Washington University), a subsidiary of University of Washington is an educational university that provides patient care and research services in the US. The university provides various courses of bachelor’s, master’s, and doctoral degrees in a wide range o …
  • Hooker Furniture Corporation (HOFT)：企業の財務・戦略的SWOT分析
    Hooker Furniture Corporation (HOFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ortivus AB (ORTI B)：企業の財務・戦略的SWOT分析
    Summary Ortivus AB (Ortivus) is a supplier of mobile solutions for emergency medical care. The company develops and offers cardiology, and mobile monitoring and communication solutions. Its products include MobiMed Smart, CoroNet, excense heart record system and excense decision support healthcare s …
  • Micro Focus International Plc (MCRO)：企業の財務・戦略的SWOT分析
    Micro Focus International Plc (MCRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Solid Biosciences Inc (SLDB)：製薬・医療：M&Aディール及び事業提携情報
    Summary Solid Biosciences Inc (Solid Biosciences) is a life science company focused on developing therapies for duchenne muscular dystrophy (DMD). Its pipeline product candidates include SGT-001, a microdystrophin gene therapy administered through adeno-associated virus (AAV) stabilizes dystrophin g …
  • Raymond James Financial Inc：戦略・SWOT・企業財務分析
    Raymond James Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Raymond James Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • TGS-NOPEC Geophysical Company ASA (TGS)：石油・ガス：M&Aディール及び事業提携情報
    Summary TGS-NOPEC Geophysical Company ASA (TGS) is a provider of exploration services. It offers multi-client geosciences data to oil and gas exploration and production companies. The company offers a range of global geophysical and geological data libraries including multi-client seismic data, magn …
  • Lincoln Educational Services Corp (LINC)：企業の財務・戦略的SWOT分析
    Summary Lincoln Educational Services Corp (Lincoln) is an educational service provider that operates schools, colleges and technical institutes. The organization offers student services including admissions, financial aid, academics, and career services. It provides educational programs in the areas …
  • Caladrius Biosciences Inc (CLBS)-医療機器分野：企業M&A・提携分析
    Summary Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc is a clinical stage development company that develops and manufactures cell therapy products. The company’s products are based on its proprietary technologies such as Dendritic Cell-Tumor Cell technology; CD34 technology; and T Regu …
  • Nippon Life Insurance Company：戦略・SWOT・企業財務分析
    Nippon Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Nippon Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Stratasys Ltd：企業の戦略・SWOT・財務情報
    Stratasys Ltd - Strategy, SWOT and Corporate Finance Report Summary Stratasys Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Wellcome Trust Sanger Institute：医療機器：M&Aディール及び事業提携情報
    Summary Wellcome Trust Sanger Institute (Sanger Institute) a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research a …
  • Chrono Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Chrono Therapeutics Inc (CTI) is a personalized medicine manufacturer that provides programmable passive transdermal drug delivery products. The company provides smartstop, a programmable smoking cessation therapy that helps people to quit smoking and improve cessation outcomes. Its wearable …
  • Prescient Therapeutics Ltd (PTX)：企業の財務・戦略的SWOT分析
    Summary Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd, is a clinical stage oncology company that develops novel drugs for the treatment of solid and hematological cancers. The company’s lead drug candidate includes PTX-200, a potent small molecule inhibitor of the …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆